eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Systematic review/Meta-analysis

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis

Paweł Kawalec, Przemysław Holko, Małgorzata Gawin, Andrzej Pilc

Arch Med Sci 2018; 14, 5: 1125–1136
Online publish date: 2018/08/13
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Clinical studies have revealed that fixed-dose combinations (FDCs) of drugs can have a better effect on blood pressure than free-equivalent combinations (FECs). Our objectives were to perform an up-to-date assessment of the effectiveness of FDCs and FECs in antihypertensive therapy, to provide more accurate results by using a stratified meta-analysis.

Material and methods
A systematic review was performed in PubMed, Web of Science, and Cochrane databases according to PRISMA guidelines. The outcomes were adherence (compliance), persistence to medication, reduction of blood pressure and the safety profile. We used the Newcastle Ottawa scale or the Delphi list for the assessment of the quality of cohort studies or clinical trials, respectively. Heterogeneity was assessed using the Cochrane Q test and I2 statistic.

Results
Of 301 abstracts screened, 26 primary studies and 2 other meta-analyses were identified, of which 12 studies were included in the meta-analyses and 3 studies were included in the narrative review. The FDC treatment is associated with a significant improvement in adherence and persistence in comparison with FEC treatment, e.g., the average medicine possession ratio increased with FDC by 13.1% (p < 0.001). For endpoints correlated with higher adherence (e.g., a reduction in blood pressure), a nonsignificant benefit was observed for FDCs. Moreover, it was demonstrated that higher adherence can lead to a lower risk of cardiovascular events.

Conclusions
In comparison with FECs, the FDC treatment is associated with a significant improvement in the cooperation between a doctor and a patient and with increased patients’ adherence to the treatment schedule.

keywords:

fixed-dose combinations, free-equivalent combinations, hypertension

references:
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
Heidenreich P, Trogdon J, Khavjou O, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-44.
Psaty B, Furberg C, Kuller L, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. Arch Intern Med 2001; 161: 1183-92.
Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-72.
Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012; 125: 188-97.
Black H, Elliott W, Neaton J, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12-8.
Brown MJ, McInnes GT, Papst CC, Zhang J, Mac-Donald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-20.
Neutel JM, Mancia G, Black HR, et al.; TEAMSTA Severe HTN Study Investigators. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA Severe HTN Study. J Clin Hypertens 2012; 14: 206-15.
Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64: 1279-83.
Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722-32.
Baser O, Andrews LM, Wang L, et al. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine singe-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ 2011; 14: 576-83.
Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs. free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 2011; 13: 898-909.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa.
Verhagen A, de Vet H, de Brie R, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-41.
Asplund J, Danielson M, Ohman P. Patients compliance in hypertension – the importance of number of tablets. Br J Clin Pharmacol 1984; 17: 547-52.
Schweizer J, Hilsmann U, Neumann G, Handrock R, Klebs S. Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination. Curr Med Res Opin 2007; 23: 2877-85.
Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 324-32.
Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64: 1279-83.
Dickson M, Plauschinat CA. Compliance with antihyper-tensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/ benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8: 45-50.
Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008; 24: 2597-607.
Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 2008; 18: 204-9.
Hess G. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. PT 2008; 33: 652-66.
Shaya FT, Du D, Gbarayor CM, et al. Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc 2009; 101: 34-9.
Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010; 26: 2065-76.
Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010; 26: 2877-87.
Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis 2013; 7: 27-39.
Viechtbauer W. Conducting meta analysis in R with the metafor package. J Statist Software 2010; 36: 1-48.
Solomon LR, Dawes PM. Treatment of essential hypertension with a combination of propranolol and bendrofluazide. J Int Med Res 1980; 8: 34-7.
Nissinen A, Tuomilehto J. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. Pharmatherapeutica 1980; 2: 462-8.
Olvera R, Moguel R, Meaney E, Gonzalez V, Sanchez S. Use of a combination of lisinopril and hydrochlorothiazide in the treatment of arterial-hypertension. Curr Ther Res Clin Exp 1991; 49: 155-61.
Mancia G, Omboni S. Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. Blood Pressure 2004; 13: 11-7.
Bengtsson C, Schroder G, Malmberg L, Abrahamsson L, Sandrstedt R. Antihypertensive treatment with diuretics and beta-blockers in free and fixed-ratio combination: a clinical trial with oxprenolol/chlorthalidone in a fixed-ratio combination. Clin Ther 1979; 2: 114-23.
Ebbutt AF, Elsdon-Dew RW. A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K. J Int Med Res 1979; 7: 524-7.
Forrest WA. An open comparison between free and a fixed combination of diuretic and beta-blocker in the management of essential hypertension. J Int Med Res 1980; 8: 127-31.
Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl): 2-6.
Jackson K, Brixner D, Oderda G, Oberg B, Sheng X, Keskinaslan A. Compliance and persistence of fixed dose versus free dose combination therapy with valsartan and HCTZ for patients with hypertension [abstract]. Value Health 2006; 9: A363.
Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007; 63: 1055-61.
Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008; 30: 1558-63.
Barron JJ, Daniel G, Makin C, et al. Treatment modifications and resource use for fixed-dose vs separate-agent antihypertensive regimens. Drug Benefit Trends 2008; 20: 226-47.
Malesker MA, Hilleman DE. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care 2010; 19: 36-42.
Bronsert MR, Henderson WG, Valuck R, et al. Comparative effectiveness of antihyperthensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. J Am Board Fam Med 2013; 26: 529-38.
Kumagai N, Onishi K, Hoshino K, et al. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens 2013; 35: 355-60.
Ulusoy S, Ozkan G, Konca C, Kaynar K. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability. Hypertens Res 2012; 35: 1111-7.
Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-20.
Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010; 25: 495-503.
Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe